Navigation Links
Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
Date:4/25/2011

merase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. PSI-7977, an unpartnered uracil nucleotide analog that is currently dosing in three Phase 2b studies in patients with HCV genotypes 1 through 6 and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and a 14-day combination study with PSI-7977. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and one interferon free combination trial. These clinical studies are being conducted through a strategic collaboration with Roche.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities an
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 Z-Medica, a ... it has launched the first-ever line of products designed ... The line includes QuikClot ® EMS 4x4 Dressing, ... ® EMS Rolled Gauze™, all custom-designed to help ... they can be transported to a hospital or trauma ...
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... , May 22, 2013 Hemoglobin A1C ... patients with Type 2 diabetes, while modest improvements ... health outcomes and can lead to substantial healthcare ... the International Society for Pharmacoeconomics and Outcomes Research ... two studies, sponsored by Valeritas, makers of the ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... 21, 2011  BARRX Medical Inc., a leader in developing ... to remove precancerous tissue from the gastrointestinal tract, announces ... be acquired by Covidien.  Covidien is a leading global ... advanced energy-based devices.  Covidien will acquire ...
... NORRITON, Pa., Nov. 21, 2011 Tengion, Inc. (NASDAQ: ... today announced that Brian Davis, Vice President Finance and ... upcoming Piper Jaffray 23rd Annual Health Care Conference on ... A live audio webcast of the presentation ...
Cached Medicine Technology:BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...
(Date:5/22/2013)... Hopkins researchers report that hospitals may be reaping ... complicated by preventable bloodstream infections contracted in their ... study, reported online in the American Journal ... an ICU patient who develops an avoidable central ... more to care for than a similar infection-free ...
(Date:5/22/2013)... 22, 2013 Registered Dietitian and Founder of ... on Tatalou.com sharing a recipe for making energy bars at ... Energy Bars ,” takes a recipe modified from one ... , “Every day it gets more and more difficult to ... Chevreau. “The size of the nutrition label continues to grow ...
(Date:5/22/2013)... Unknown to the citizens of Wichita, Kansas a tornado was ... it struck, the city’s warning siren started blaring and informed ... to reach safety and prevented any deaths or injuries. ... product that will increase safety in the workplace if a ... System provides employees with the same type of warning ...
(Date:5/22/2013)... (HealthDay News) -- People with heart failure are more ... gland that is even mildly underactive, according to a ... researchers found an increased risk of death linked to ... "This study is the first to show that African-Americans ... than patients of other racial and ethnic groups," Dr. ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2Health News:Underactive Thyroid and Heart Failure a Bad Combination: Study 2
... BOARD,S INTERESTS ARE NOT ALIGNED WITH STOCKHOLDERSADVOCAT BOARD NEEDS ... Calif., May 19 Bristol Investment Fund, Ltd. ("Bristol") ... the stockholders of Advocat, Inc. (the "Company") (Nasdaq: ... highly qualified and independent director nominees, Paul Kessler and ...
... microsite (www.meettheburns.com) targets first time athlete,s foot sufferers ... Schering-Plough Corporation (NYSE: SGP ... an antifungal spray for the treatment of athlete,s ... liquid spray and deodorant powder spray.(Photo: ...
... Sustainable Healthcare CHICAGO, May 19 Practice ... to environmentally responsible healthcare, has announced its ... competitive awards are given to institutions within ... reduce the facility,s environmental footprint.Fletcher Allen Health ...
... differ across continents, posing challenges to drug launches. ... regulatory environment of the European Union (EU) and ... less price controlled markets witness quicker launches, while ... industry, along with regulatory agencies, has been working ...
... 2009 The International Diabetes Federation (IDF), International ... (WHF) today issued a joint statement that calls ... epidemic of non-communicable diseases (NCDs), responsible for 35 ... substantial increase in funding for NCDs and greater ...
... in the Los Angeles , California area will be ... describe a revolutionary laser liposuction procedure. Dr. ... Center is one of the first surgeons on ... laser liposuction technique -- that not only melts fat, ...
Cached Medicine News:Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 2Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 3Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 4Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 5Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 6Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 7Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 8Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 9Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 3Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 4Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 5Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 6Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 7Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 8Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 3Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 4Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 2Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 3Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 4Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 2Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 3Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 4
The Diamedix immunosimplicity® Is- Rheumatoid Factor Test Kit is an EIA procedure intended for the quantitation of IgM antibodies to IgG antigen. The results are reported in IU/mL, traceable to t...
... The SYNCHRON CX4 Delta Specialty / ... access analyzer that can consolidate Drugs ... testing, such as thyroid, HbA1c and ... CX4 Delta offers a level of ...
Inquire...
... Analyzer is a high precision optical system ... of the anterior eye segment, based on ... a Placido Disk. , GALILEI combines the ... high accuracy curvature data, while Scheimpflug imaging ...
Medicine Products: